Riabni Purple Book BLA 761140
- BLA number
- 761140
- Proprietary names
- Riabni
- Proper names
- rituximab-arrx
- Applicant
- Amgen Inc.
- Center
- CDER
- First observed release
- 2020-12-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Riabni | rituximab-arrx | 351(k) Biosimilar | 100MG/10ML (10MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2020-12-17 | |
| 002 | Riabni | rituximab-arrx | 351(k) Biosimilar | 500MG/50ML (10MG/ML) | Injection | Intravenous | Single-Dose Vial | Rx | Licensed | 2020-12-17 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2020-12-01 | N | 001 | Riabni | 351(k) Biosimilar | Rx | Amgen, Inc. |
| 2020-12-01 | N | 002 | Riabni | 351(k) Biosimilar | Rx | Amgen, Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2020-12-01 | 001 | Riabni | 351(k) Biosimilar | Rx | Licensed | 2020-12-17 |
| 2020-12-01 | 002 | Riabni | 351(k) Biosimilar | Rx | Licensed | 2020-12-17 |